Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX05-N vs ERBITUX in Metastatic Colorectal Cancer
NCT07543471Phase 1Not yet recruiting
- Sponsor
- Henlius
- Start
- Jun 2026
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, randomised, double-blind trial of HLX05 in colorectal cancer (CRC) (3 arms), sponsored by Henlius. Primary endpoints: Area under the serum concentration-time curve from time 0 to 7 days and Area under the serum concentration-time curve within a dosing interval at steady state at 21 days. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
HLX05
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07543471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07543471.